This is a nonrandomized (participants may decide which drugs they want to take), multi-site, open-label trial to evaluate a novel two-drug combination regimen (MK-3682 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN taken once-a-day) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.
Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
To read the entire clinical trial description, click here
The study is recruiting HIV/HCV coinfected people with genotype 1 through 6 to determine the safety and effectiveness of the combination of ABT-493 plus ABT-530. The study is enrolling non-cirrhotic patients who will be treated for 8 weeks and compensated cirrhotic patients who will be treated for 12 weeks. In the completed Phase II studies the combination cured 97% to 100% of HCV genotype 1, 2 and 3 patients.
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)
To view the entire study description click here